Recent Promotions
USP40 Knockout HEK293 Cell Line
Cat.No.:
EDJ-KQ16080
Species:
Human
Cell Name:
HEK293
Gene:
USP40
Gene ID:
55230
Size:
1×10⁶cells
USP40 Knockout Cell Line (HEK293) is an exclusive upgraded CRISPR/Cas9 system-mediated gene knockout cell, with the advantages of Optimized Strategy Design, Efficient Cell Transfection, High-Performance Cas9 Protein and Hassle-Free Cell Selection.
| Cat.No. | EDJ-KQ16080 |
|---|---|
| Product Name | USP40 Knockout Cell Line (HEK293) |
| Cell Line | HEK293 |
| Cellosaurus ID | CVCL_0045 |
| Cell Line Synonyms | Hek293, HEK-293, HEK/293, (HEK)293, HEK 293, HEK,293, 293, 293 HEK, 293 Ad5, Graham 293, Graham-293, Human Embryonic Kidney 293 |
| Gene | |
| NCBI Gene ID | |
| Gene Synonyms | - |
| Summary |
Modification of cellular proteins by ubiquitin is an essential regulatory mechanism controlled by the coordinated action of multiple ubiquitin-conjugating and deubiquitinating enzymes. USP40 belongs to a large family of cysteine proteases that function as deubiquitinating enzymes (Quesada et al., 2004 [PubMed 14715245]).[supplied by OMIM, Mar 2008]
|
| Associated Diseases | Non-tumor |
| Morphology | Adherent |
| Passage Ratio | 1/5,2days |
| Complete Culture Medium | DMEM + 10% FBS |
| Freezing Medium | 95% Complete culture medium+ 5% DMSO |
| QC | Indels validated by Sanger sequencing; sterility confirmed via microbial testing. |
* For research use only. Not intended for use in humans or animals, including clinical, therapeutic, or diagnostic purposes.
| Loci | STR Info (Sample Cell) Sample Cell Line: HEK293 | STR Info (Cell bank) Cell Line: HEK293 | ||
| Allele1 | Allele2 | Allele1 | Allele2 | |
| Amelogenin | X | X | ||
| CSF1P0 | 12 | 11 | 12 | |
| D2S1338 | 19 | 19 | ||
| D3S1358 | 15 | 17 | 15 | 17 |
| D5S818 | 8 | 8 | 9 | |
| D7S820 | 11 | 12 | 11 | 12 |
| D8S1179 | 12 | 14 | 12 | 14 |
| D13S317 | 12 | 14 | 12 | 14 |
| D16S539 | 9 | 13 | 9 | 13 |
| D18S51 | 17 | 18 | 17 | 18 |
| D19S433 | 15 | 18 | 15 | 18 |
| D21S11 | 28 | 30.2 | 28 | 30.2 |
| FGA | 23 | 23 | ||
| Penta D | 9 | 10 | 9 | 10 |
| Penta E | 7 | 15 | 7 | 15 |
| TH01 | 7 | 9.3 | 7 | 9.3 |
| TPOX | 11 | 11 | ||
| vWA | 16 | 19 | 16 | 19 |
| D6S1043 | 11 | 11 | ||
| D12S391 | 19 | 21 | 11 | 15 |
| D2S441 | 11 | 15 | 11 | 15 |
* STR authentication data of this cell line matches with that of cell lines sourced from ATCC, DSMZ, JCRB, and RIKEN databases.
Conclusion: The STR identification of this cell is correct.
Conclusion: The STR identification of this cell is correct.
* Research Use Disclaimer: Content is generated from publicly available research data, bioinformatic resources, and computational analyses for research reference only.
Research Publications
USP40 protects podocytes by deubiquitylating integrin β1.
IF=2.2
Biochemical and biophysical research communications
The mechanisms leading to the formation of sclerotic lesions in focal segmental glomerulosclerosis (FSGS) remain incompletely understood; however, podocyte detachment and loss are considered key pathogenic events. Ubiquitin-specific protease 40 (USP40) is a deubiquitylating enzyme expressed in podocytes. In the present study, we investigated the role of USP40 in podocytes, focusing on its impact on the adhesion molecule integrin β1, which is essential for anchoring podocytes to the glomerular basement membrane. When USP40 knockout mice were subjected to an experimental FSGS model, they exhibited significantly more severe proteinuria and glomerulosclerosis than control mice, along with a marked reduction in podocyte number and integrin β1 expression. Consistently, knockdown of USP40 in cultured podocytes resulted in decreased integrin β1 expression and impaired adhesive properties compared with sham-treated cells. In HEK293 cells transfected with ubiquitin constructs, USP40 suppressed integrin β1 monoubiquitylation. In a separate internalization assay, USP40 prevented the clathrin-mediated endocytosis of integrin β1. In USP40 knockout mice, clathrin-coated vesicles colocalizing with integrin β1 were more frequently observed in podocyte foot processes than in control mice. Together, these findings suggest that USP40 functions as a deubiquitylating enzyme that stabilizes integrin β1 at the podocyte plasma membrane by preventing its endocytosis. We therefore propose that the USP40-integrin β1 axis represents a potential therapeutic target for FSGS.
This KO model may be useful for:
- Investigating deubiquitination mechanisms in podocyte biology
- Studying integrin β1 stability and signaling pathways
- Exploring protective roles against podocyte injury and proteinuria
- Evaluating therapeutic targets for kidney diseases involving cell-matrix adhesion
- Functional validation of USP40 in ubiquitin-proteasome system regulation